Recent studies highlight the potential of a new blood test, PrecivityAD2, in diagnosing Alzheimer’s disease with about 90% accuracy by detecting biomarkers like amyloid beta and tau proteins. Though promising, these tests are currently only available in research settings and have limitations such as small sample sizes and exclusion of other cognitive diseases. Experts caution that while the tests improve diagnostic accuracy compared to traditional methods, they do not directly diagnose Alzheimer’s but indicate the likelihood of the disease. The tests could aid in early diagnosis, allowing for timely treatment and planning, but effective treatments for Alzheimer’s remain limited and controversial. New approaches, such as using ultrasound to reduce beta-amyloid plaques, are also being explored, adding to the potential arsenal against Alzheimer’s. However, further studies and FDA approvals are needed before these tests and treatments become widely available.